glp 1 agonist review Glucagon‐like peptide agonists: A prospective - Mariam - 2024 - Endocrinology, Diabetes & Metabolism GLP-1 Agonists For Obesity In

Populations most likely to benefit include individuals with obesity or central adiposity, insulin resistance or type 2 diabetes, metabolic dysfunctionassociated fatty liver disease, or elevated cardiovascular risk

Before your first injection, staying well hydrated and eating light, balanced meals can help minimize potential side effects like nausea

180,181,183 GLP-1 also activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, which is crucial for maintaining the survival and function of pancreatic -cells

A recent meta-analysis of 14 RCTs in adolescents with overweight or obesity (including those with type 2 diabetes) confirmed that GLP-1 RA therapy led to mean HbA1c reductions (0.34% risk difference) and weight loss (4.3 kg) relative to the control group (34)

WARNING: Risk of Thyroid C-Cell Tumors In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)

Switching from a short-acting to a long-acting GLP-1 receptor agonist could lead to small transient increases in FPG, as shown in the DURATION-1 trial (61)